Rationale: Pulmonary arterial hypertension (PAH) is characterized by significant exercise intolerance, which is multifactorial and involves skeletal muscle alterations. There is growing evidence that microRNAs (miRs) are involved in PAH pathogenesis. Objectives: We hypothesized that miR-126, an endothelial-specific, proangiogenic miR, is down-regulated in the peripheral muscles of patients with PAH, which would account for skeletal muscle microcirculation loss and exercise intolerance. Measurements and Main Results: Patients with PAH displayed decreases in exercise capacity (V. o2max) and microcirculation loss on quadriceps muscle biopsy (in CD31+ immunofluorescence experiments) compared to control subjects. Exercise capacity correlated with muscle capillarity (r = 0.84, P < 0.01). At the cellular level, vascular endothelial growth factor (VEGF) and VEGF receptor 2 expression were similar in both groups. Conversely, PAH was associated with a 60% decrease in miR-126 expression in a quantitative reverse transcriptase polymerase chain reaction experiment (P < 0.01), resulting in up-regulation of its targeted protein, Sprouty-related, EVH1 domain–containing protein 1 (SPRED-1), and a marked decrease in the downstream effectors of the VEGF pathway, p-Raf/Raf and p-ERK/ERK, as determined by immunoblot analysis. Using freshly isolated CD31+ cells from human quadriceps biopsies, we found that the down-regulation of miR-126 in PAH triggered the activation of SPRED-1, impairing the angiogenic response (Matrigel assay). These abnormalities were reversed by treating the PAH cells with miR-126 mimic, whereas inhibition of miR-126 (antagomir) in healthy CD31+ cells fully mimicked the PAH phenotype. Finally, miR-126 down-regulation in skeletal muscle of healthy rats decreased muscle capillarity in immunofluorescence assays (P < 0.05) and exercise tolerance in treadmill tests (P < 0.05), whereas miR-126 up-regulation increased them in monocrotaline PAH rats. Conclusions: We demonstrate for the first time that exercise intolerance in PAH is associated with skeletal muscle microcirculation loss and impaired angiogenesis secondary to miR-126 down-regulation.
Little is known about limb muscle abnormalities in mild COPD. Inactivity and systemic inflammation could play a role in the development of limb muscle dysfunction in COPD. The objective of the present study was to characterize quadriceps function, enzymatic activities and morphometry, levels of plasma inflammatory markers and physical activity levels in daily life (PAdl) in patients with mild COPD (GOLD 1).
28 June 2023 in Journal of Pharmaceutical Sciences
Background: Pembrolizumab is a monoclonal antibody (mAb) approved for treating Non-Small Cell Lung Cancer (NSCLC), melanoma and lymphomas. Commercialized in single-size (100 mg/4 mL) vials, the pembrolizumab solution contains no preservative. As such, the manufacturer recommends using pembrolizumab vials only once, and thus, to rapidly dispose of any unused portion. Thus, appreciable amounts of this costly product are wasted. Objective: To evaluate the physical, chemical and microbiological stability of pembrolizumab vial leftovers stored at room temperature or at 4 °C, 7 and 14 days after first vial puncturing. Methods: Following pH assessments, submicronic aggregation and turbidity of pembrolizumab were measured by dynamic light scattering (DLS) and spectrophotometry, respectively. In addition, SE-HPLC (size-exclusion high-performance liquid chromatography), IEX-HPLC (ion exchange HPLC) and peptide mapping HPLC served to respectively evaluate aggregation and fragmentation, distribution of charge and primary structure of pembrolizumab. Incubation at 37 °C for 48 h of pembrolizumab vial leftovers on blood agar plates was used to determine their microbiological stability. Results: Physical, chemical and microbiological stability of pembrolizumab leftovers was demonstrated for at least two full weeks. Conclusions: These results argue forcefully in favor of allowing prolongation of pembrolizumab vial leftovers usage well beyond a single day.
3 April 2026 in Journal of Antimicrobial Chemotherapy
Background and objectives: Optimal cefazolin dosing for surgical prophylaxis in patients with severe obesity remains controversial, particularly regarding tissue exposure at the surgical site. Plasma concentrations may not reliably reflect pharmacologically active antibiotic levels in target tissues. This study aims to characterize total and calculated unbound concentrations of cefazolin in subcutaneous adipose tissue, dermis and plasma in patients with severe obesity undergoing bariatric surgery, and to assess pharmacodynamic target attainment across clinically relevant MIC thresholds. Methods: In this prospective observational study, patients undergoing sleeve gastrectomy received cefazolin prophylaxis according to current guidelines (2 or 3 g intravenously). Plasma, dermis and adipose tissue samples were collected at incision (T0), 30 min (T30) and end of surgery (Tend). Total cefazolin concentrations were quantified using validated HPLC methods. Concentration–time profiles were analysed using linear mixed–effects models adjusted for age, BMI and creatinine clearance. Target attainment was evaluated at MIC thresholds of 2, 4 and 8 mg/L. Results: Dermis and plasma total cefazolin concentrations consistently exceeded all MIC thresholds in both dosing groups, whereas adipose tissue concentrations were more variable, with reduced attainment at higher MICs. Calculated unbound cefazolin concentrations demonstrated marked matrix–dependent differences: plasma unbound levels consistently exceeded all targets, dermal unbound concentrations increased significantly from T0 to Tend and adipose tissue unbound concentrations remained low across all time points. Increasing the dose from 2 to 3 g modestly improved total adipose tissue target attainment but did not substantially enhance unbound adipose tissue exposure. No surgical site infections occurred. Conclusions: In patients with severe obesity, guideline–recommended cefazolin dosing provides adequate plasma and dermis exposure but fails to ensure reliable unbound adipose tissue concentrations. These findings highlight the limitations of plasma-based assessments and support tissue–informed, individualized prophylactic strategies in bariatric surgery.
Background: Ceftobiprole medocaril (Zevtera®) is an injectable broad-spectrum antibiotic. Objective: We aim to show that ceftobiprole initiated in hospital may be continued at home through Outpatient Parenteral Antibiotic Therapy (OPAT). Methods: Solutions of ceftobiprole at 2.0 and 2.8 mg/mL were prepared in PVC bags from 500 mg vials and stored at room temperature (RT) or 4 °C. Each sample was analyzed in triplicate samples using high-performance liquid chromatography (HPLC) at multiple time points over a 120 h period. Additionally, 2.5 mg/mL ceftobiprole solutions were prepared in Intermate® infusion devices (n = 3 preparations) and stored at 4 °C. Samples were collected on multiple days from Day 0 to Day 9, both immediately post-refrigeration and after 8 h at RT and analyzed in triplicate. Results: PVC bag solutions retained ≥90% of their initial concentrations. At RT, residual concentration was 90.9% (2.0 mg/mL) and 92.0% (2.8 mg/mL) after 24 h. At 4 °C, the 2.0 mg/mL formulation retained 90.8% after 120 h, and the 2.8 mg/mL formulation retained 90.2% after 96 h. Intermate® devices stored nine days at 4 °C and exposed to RT for 8 h retained ≥90% of the initial concentration of ceftobiprole (2.5 mg/mL; 93.3% before RT exposure; 91.1% after). Conclusions: Ceftobiprole medocaril exhibits sufficient physicochemical stability for OPAT use in PVC bags and Intermate® infusion device under tested conditions.